SAFETY DATA SHEET

Anti-CTLA-4 Antibody (Ipilimumab Biosimilar)

Catalog No. CTLA4-AB001

1. PRODUCT AND COMPANY INFORMATION

1.1 Catalog Number	CTLA4-AB001
1.2 Product Name	Anti-CTLA-4 Antibody (Ipilimumab Biosimilar)
1.3 Supplier / Manufacturer	Suzhou Puweituo Biotechnology Co., Ltd.
Telephone / E-mail	400-829-0116 | order@provetop.com
1.4 Application of the substance or mixture	For Research Use Only.

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture	Not a hazardous substance or mixture.
2.2 GHS Label elements, including precautionary statements	Not a hazardous substance or mixture.
2.3 Other hazards	None known.

3. COMPOSITION / INFORMATION ON INGREDIENTS

3.1 Ingredients	This product does not contain any hazardous substances and carcinogens.
Carcinogenicity	This product does not contain any hazardous substances and carcinogens.

4. FIRST AID MEASURES

4.1 Description of first aid measures - Eye contact	Flush with copious amounts of water for at least 15 minutes. Consult a doctor if necessary.
Skin contact	Rinse with plenty of water. Remove contaminated clothing and wash before reuse.
Inhalation	Move to fresh air. Consult a doctor if breathing becomes difficult.
Ingestion	Rinse mouth and drink water if swallowed. Do not induce vomiting without professional guidance.
4.2 Most important symptoms and effects	Not applicable.

Anti-CTLA-4 Antibody (Ipilimumab Biosimilar)
Catalog No. CTLA4-AB001

5. FIRE FIGHTING MEASURES

5.1 Suitable extinguishing media	Use water spray, dry chemical, foam, or carbon dioxide as appropriate for the surrounding fire.
5.2 Unsuitable extinguishing media	No information available.
5.3 Precautions for fire-fighters	Wear suitable protective clothing and self-contained breathing apparatus where required.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions	Use personal protective equipment and minimize direct contact with skin or eyes.
6.2 Methods for clean up	Collect material in appropriate containers for disposal. Ventilate and wash the affected area.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling	Avoid contact with eyes, skin and clothing. Follow standard laboratory hygiene practices.
7.2 Storage	Store according to the approved product data sheet and certificate of analysis.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters	Contains no substances with occupational exposure limit values.
8.2 Engineering controls	Ensure adequate ventilation, especially in confined areas.
8.3 Eye protection	Wear appropriate safety glasses.
Skin and body protection	Wear appropriate protective clothing and gloves.

9. CHEMICAL AND PHYSICAL PROPERTIES

Appearance	Lyophilized powder or liquid.
Other information	No further information available.

Anti-CTLA-4 Antibody (Ipilimumab Biosimilar)
Catalog No. CTLA4-AB001

10. STABILITY AND REACTIVITY

Chemical stability	Stable under recommended storage conditions.
Hazardous reactions	No hazardous polymerization reaction occurs.

11. TOXICOLOGICAL INFORMATION

General information	Handle in accordance with standard laboratory practices. Avoid contact with eyes, skin and clothing.

12. ECOLOGICAL INFORMATION

General information	Avoid release to the environment.

13. DISPOSAL INFORMATION

Disposal considerations	Dispose of this product and its container in accordance with local regulations.

14. TRANSPORTATION INFORMATION

IATA DGR / IMDG Code	Non-hazardous for transport.

15. REGULATORY INFORMATION

Regulatory information	No information available.

16. OTHER INFORMATION

16.1 Disclaimer	The information is provided as a guide and does not constitute a warranty. Use all materials with appropriate laboratory caution.
16.2 Further information	Not for human use.